Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-08-25
2001-02-13
Moezie, F. T. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C514S171000, C514S177000, C514S178000, C514S182000, C514S415000, C514S903000, C424S580000, C424S583000
Reexamination Certificate
active
06187750
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to hormone therapy as a treatment for patients with symptoms consistent with multiple sclerosis.
2. Background
It is known that the levels of a variety of hormones drop substantially with age. These include human growth hormone, sex hormones, pineal, adrenal, thyroid, and thymus hormones. Hormonal replenishment methods employed as anti-aging treatments have been developed. An example of such method is described in U.S. Pat. No. 8,855,920. The utility of this method in connection with certain degenerative diseases, often associated with hormonal deficiencies due to aging, is also known in the art.
In contrast, Multiple Sclerosis (MS) is not a disease associated with degenerative conditions associated with old age. Rather, MS strikes mainly young adults and is the most common neurologic cause of disability in that age group. Overall, MS affects approximately 300,000 Americans.
MS is thought to be an autoimmune illness, wherein the immune system mistakenly recognizes normal brain and spinal tissue as “foreign” and attacks them, resulting in inflammation and damage. Myelin, the insulative material surrounding axons in nerve cells, are particularly affected by MS. In patients, the inflammation disrupts myelin, sometimes destroying the axons thus impeding the connections between nerve cells. The region of demyelination and inflammation within the brain or spinal cord is called a “plaque” and ranges anywhere from millimeters to more than a centimeter in diameter.
Actual MS symptoms appear to reflect the number and severity of plaques as well as their location at important sites within the nervous system. Mild sensory symptoms, e.g., tingling, burning, itching, may result. Typically, however, no diagnosis of MS is made until severe symptoms develop, such as weakness, paralysis or numbness of limbs, loss of vision, imbalance, chronic pain or chronic fatigue. The long term consequences of MS can be very debilitating. In some studies, 50% of patients were disabled within ten years and fewer than two thirds were able to walk after thirty years.
In common diagnosis, MS is found by excluding all other potential conditions from consideration. Formerly diagnostic chemical tests of cerebro-spinal fluid determined the presence of MS. This, however, has given way in recent years to magnetic resonance imaging (MRI) scans of the brain as the preferred diagnostic method. Brain MRI scans are abnormal in the vast majority of MS victims. Areas of abnormal brightness, suggesting increased water content, appear on “T2 weighted” scans; dark areas on “T1 weighted” scans suggest focal areas of tissue destruction; and abnormal brightness after a dye is injected for enhancement into the patient's bloodstream suggest that inflammation has damaged the blood-brain barrier. Again, as these symptoms are present also in other neurologic conditions, the diagnosis of MS is not made from these symptoms alone. This diagnosis results by testing done over time.
Various drugs, including natural immune substances such as beta-interferon, have proved effective in treating the physical symptoms of MS and reducing their frequency. Recently studies with animals employing induced experimental autoimmune encephalomyelitis (EAE), an animal model of MS, has shown that growth factor hormones, including Insulin-like Growth Factor hormones (IGF) may promote myelin regeneration, reducing and sometimes eliminating inflammatory lesions and reducing other clinical deficits in EAE subjects. In one study adult female mice having induced EAE were injected subcutaneously with 0.6 mg of IGF over a ten day period. Another group of EAE-induced mice were given placebos. Those treated with IGF-I exhibited reduced deficits and reduced numbers and sizes of inflammatory, demyelinating and demyelinated lesions.
SUMMARY
The invention relates to a hormone replenishment method employed as a treatment for subjects with symptoms consistent with Multiple Sclerosis (MS). The method includes, in one aspect, administering a regimen of human growth hormone (HGH) of less than 0.5 mg per day.
REFERENCES:
patent: 4727041 (1988-02-01), Aroonsakul
patent: 4791099 (1988-12-01), Aroonsakul
patent: 4897389 (1990-01-01), Aroonsakul
patent: 4898856 (1990-02-01), Aroonsakul
patent: 4898857 (1990-02-01), Aroonsakul
patent: 4902680 (1990-02-01), Aroonsakul
patent: 5017470 (1991-05-01), Aroonsakul
patent: 5391381 (1995-02-01), Wong et al.
patent: 5397771 (1995-03-01), Bechgaard et al.
patent: 5424199 (1995-06-01), Goeddel et al.
patent: 5434146 (1995-07-01), Labrie et al.
patent: 5550107 (1996-08-01), Labrie
patent: 5563131 (1996-10-01), Berliner et al.
patent: 5691169 (1997-11-01), Dalbage et al.
patent: 5691325 (1997-11-01), Sandyk
patent: 5855920 (1999-01-01), Chein
patent: WO 95/32991 (1995-07-01), None
“Administration of Human Somatotropin in Levodopa-Treated Patients With Parkinsonism” by Paul S. Papavasiliou et al.,Arch Neurol,vol. 36, Oct. 1979.
“Long-Term Influence of Levodopa on Bone Mass and Growth Hormone in Postmenopausal Women with Parkinson's Disease” by H. Rico, et al.,Clinical Neuropharmacology,vol. 10, No. 1, pp. 87-91, 1987.
“Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease” by Bonnie M. Davis, MD, et al.,Journal of the American Geriatrics Society,vol. 33, No. 11.
“Disturbances of Pituitary Function in Central Nervous System Disease” by Glenn T. Peake, MD, et al.,Medical Clinics of North America,vol. 52, No. 2, Mar. 1968.
“Growth Hormone Response in Parkinson's Disease” by J.D. Parkes, et al.,The Lancet,Feb. 28, 1976.
“Blood Levels of FSH, LH, TSH, And GH in Parkinsonian patients Before and During L-Dopa Treatment” by P.O. Lundberg,Acta Neurol. Scandinav.,vol. 48, pp. 427-432, 1972.
“Therapeutic Approaches in Parkinson's Disease: Possible Roles of Growth Hormone and Somatostatin” by George C. Cotzias, et al.,The Basal Ganglia,1976.
“Effects of Estrogen, Progestin and Combined Estrogen-Progestin Oral Contraceptive Preparations on Experimental Allergic Encephalomyelitis” by Barry G. Arnason et al., Boston, MA.
“Molecular Biology of Neurological and Psychiatric Disorders. I. Effect of Parkinsonism, Age, Sex, and L-Dopa on Platelet Monoamine Oxidase” by E.A. Zeller, et al.,Journal of Neutral Transmission,39, pp. 63-77, 1976.
“Peliosis Hepatis Report of Nine Cases” by Tsutomu Karasawa, et al.,Acta Path. Jap.,29(3), pp. 457-469, 1979.
“Orale Ovulationshemmer—Indikationen und Komplikationen aus Neurologischer Sicht” by Sigrid Poser,Fortschr. Neurol. Psychiat.,45, 1977.
“Contraccezione Orale e Sclerosi Multipla” by A. Ghezzi, et al.,Archivio per le Scienze Mediche,136, 1979.
“Estrogens and Extrapyramidal System” by P. Bedard, et al.,The Lancet,Dec. 24 & 31, 1977.
“Etude des Androgenes Plasmatiques Chez les Femmes Atteintes de Maladies Auto-Immunes” by M. Dougados, et al.,Revue du Rhumatisme,1984, 51(3), pp. 145-149.
“Observations in a Preliminary Open Trial of Estradiol Therapy for Senile Dementia-Alzheimer's Type” by Howard Fillit, et al.,Psychoneuroendocrinology,vol. 11, No. 3, pp. 337-345, 1986.
“Metabolic Effects of GH: A Rationale for Continued GH Treatment of GH-Deficient Adults After Cessation of Linear Growth” by A. Juul, et al., Department of Growth and Reproduction, University of Copenhagen, Denmark.Horm Res(Switzerland) 1995, 44 Suppl 3, pp. 64-72, ISSN 0301-0163, Journal Code GBI.
“Insulin-Like Growth Factor I Alters Peripheral Thyroid Hormone Metabolism in Humans: Comparison with Growth Hormone” by M.A. Hussain, et al., Division of Endocrinology and Metabolism, University Hospital of Zurich, Switzerland.Eur J Endocrinol(Norway) May 1996, 134(5) pp. 563-7, ISSN 0804-4643, Journal Code BXU.
“Improved Final Height in Girls with Turner's Syndrome Treated with Growth Hormone and Oxandrolone” by K.O. Nilsson, et al., Department of Pediatrics, University Hospital Malmo, Sweden.J Clin Endocrinol Metab(United States) Feb. 1996, 81(2) pp. 635-40, ISSN 0021-972X, Journal Code HRB.
“Insulin, Insulin-Like Growth Factor-Binding Prote
Blakely , Sokoloff, Taylor & Zafman LLP
Everyoung Technologies, Inc.
Moezie F. T.
LandOfFree
Method of hormone treatment for patients with symptoms... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of hormone treatment for patients with symptoms..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of hormone treatment for patients with symptoms... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2605882